{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for lactic root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
HERBALIFE SKIN 7 DAY RESULTS KIT
Source URL:
First approved in 1974
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Status:
Possibly Marketed Outside US
Source:
NCT03154515: Phase 4 Interventional Completed Common Cold
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ingavirin is pentanedioic acid imidazolyl ethanamide used for the treatment of Influenza and Common Cold in Russia and some other countries. The mechanism of action is implemented at the level of infected cells due to the stimulation of innate immunity factors suppressed by viral proteins. The drug causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced α-interferon-producing ability of blood leukocytes, stimulates the γ-interferon-producing ability of leukocytes.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Acetyl-11-keto-beta-boswellic acid (AKBA), a pentacyclic triterpene, is a component of gum resin of Boswellia serrata. It inhibits 5-lipoxygenase in a selective, enzyme directed, non-redox, and noncompetitive manner. In addition, AKBA inhibited topoisomerase I. It induces apoptosis and exerts antineoplastic properties. 5-LOXIN, a dietary supplement ingredient (Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid) is effective in reducing pain and improving physical functioning in osteoarthritis patients.
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M020
(2017)
Source URL:
First approved in 1992
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT00001296: Phase 3 Interventional Completed Melanoma
(1992)
Source URL:
Class:
PROTEIN
